XTalks

APRIL 18, 2024

The Elecsys pTau217 assay is designed to detect amyloid pathology, a hallmark of Alzheimer’s disease, by measuring phosphorylated tau protein in human plasma. Previously, Roche secured an FDA breakthrough tag for another one of its Alzheimer’s blood tests that detects levels of pTau-181 and ApoE4 (apolipoprotein e4).

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

Drug Discovery World

NOVEMBER 28, 2023

Importance of healthy mitochondrial function Dysfunctional mitochondria are usually tagged for removal via mitophagy with a protein ‘flag’ called ubiquitin. These new findings suggest that maintaining healthy mitochondrial function by blocking USP30 may slow or even stop the progression of pathology which drives PD.

In-Vivo 52

In-Vivo Protein Drugs Research 52

Drug Discovery World

OCTOBER 31, 2023

The newly inserted IDS gene produces an IDS enzyme that contains a proprietary ApoEII-tagged sequence, which can bind to ApoE-dependent receptors on the blood brain barrier, and move enzyme into the brain more efficiently, thus potentially normalising brain pathology.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

Rethinking Clinical Trials

OCTOBER 19, 2022

Professor of Medicine and Pathology, Microbiology & Immunology. Johns Hopkins Berman Institute of Bioethics. Tanya Matthews, PhD. HRPP Director. Kaiser Permanente Washington. Crofford, MD. Wilson Family Chair in Medicine. Chief, Division of Rheumatology. Vanderbilt University Medical Center. Ethics, IRB, FM-TIPS. Key Points.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Medicine 130

The Pharma Data

OCTOBER 9, 2021

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies.

Antibody 52

Antibody In-Vitro Trials Development 52

XTalks

JUNE 9, 2021

Aducanumab Controversy and Price Tag. Of the three studies, two were Phase III trials — the EMERGE and ENGAGE studies — which involved patients with early stages of Alzheimer’s disease (mild cognitive impairment and mild dementia) with confirmed presence of amyloid pathology.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

Drug Discovery World

FEBRUARY 9, 2023

At the same time, we are developing a better understanding of disease pathology, leading to a more complicated picture of how diseases manifest. The second scenario is that a better understanding of complex disease pathology will unlock new insights that lead to new, more effective and safer therapies. This creates two scenarios.

Drugs 52

Drugs Development Big Data Scientist 52